Innovation Pharmaceuticals and George Mason University Announce Public Release of Laboratory Testing Results Demonstrating Brilacidin’s COVID-19 Treatment Potential

Preprint article details research conducted at George Mason’s Regional Biocontainment Laboratory: Brilacidin shown in vitro to potently inhibit SARS-CoV-2, the novel coronavirus

Read more

In Vitro Testing of Innovation Pharmaceuticals’ Brilacidin for COVID-19 Shows Consistent Anti-SARS-CoV-2 Efficacy; Manufacturing Preparation Underway for COVID-19 Clinical Trial

WAKEFIELD, Mass., July 07, 2020 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports

Read more

Screening of 11,552 Compounds Identifies Innovation Pharmaceuticals’ Brilacidin as One of the Most Promising Potential Inhibitors of the Novel Coronavirus COVID-19

WAKEFIELD, Mass., April 20, 2020 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased

Read more

Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19

WAKEFIELD, Mass., April 01, 2020 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today

Read more

Applied Biosciences Hires Former Pfizer Business Unit Chief Medical Officer as Chief Executive Officer

LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) — Applied BioSciences Corp. (OTCQB: APPB), a diversified cannabinoid-based therapeutics company focused on

Read more

Applied BioSciences Retains the Emmes Group to Partner on Therapeutic Development Initiatives

LOS ANGELES, CA / ACCESSWIRE / April 8, 2019 / Applied Biosciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused

Read more

Applied BioSciences Announces Partnership with Boxing Heavyweight Champion Shannon Briggs

LOS ANGELES, March 20, 2019 (GLOBE NEWSWIRE) — Applied Biosciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on

Read more

Applied BioSciences Announces Record Revenue

LOS ANGELES, March 18, 2019 (GLOBE NEWSWIRE) — Applied BioSciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on

Read more

Featured Interview: CEO Marco Hegyi of Grow Life, Inc. (OTCQB: PHOT)

CEO Marco Hegyi of Growlife, Inc. , discusses being a leading provider to the hydroponics industry, recent rights offering,, and helping lower the cost of cannabis production for growers.

Read more